Strata Oncology Announces Partnership with BioMed Valley Discoveries to Accelerate Enrollment in ERK Inhibitor Study

On July 29, 2020 Strata Oncology, Inc., a precision oncology company advancing molecular indications for cancer therapies, reported it has signed an agreement with BioMed Valley Discoveries, Inc. to accelerate patient identification and enrollment for BioMed Valley’s Phase 2 study of BVD-523 (ulixertinib) for patients with advanced malignancies harboring MEK or atypical BRAF alterations (non-BRAF V600E mutations) (Press release, Strata Oncology, JUL 29, 2020, View Source [SID1234562533]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Ulixertinib is a first-in-class potent and selective small molecule inhibitor of ERK1/2. BioMed Valley reported positive preliminary Phase I data for ulixertinib in patients harboring MAPK alterations, including atypical BRAF alterations.

Under the terms of the agreement and through the Strata Trial, Strata Oncology will identify patients with advanced solid tumors that harbor mutations in the MAPK signaling pathway and meet other eligibility criteria, for consideration of enrollment into BioMed Valley’s Phase 2 study. The Strata Trial, an ongoing observational study providing tumor molecular profiling for patients with advanced cancer paired with a portfolio of biomarker-guided clinical trials, is available across a network of 25+ select health systems nationwide. Through the Strata Trial, patients with advanced cancer are profiled using StrataNGSTM, a comprehensive molecular profiling test optimized for performance on tissue samples as small as 0.5mm2 surface area.

"This partnership with BioMed Valley Discoveries supports our commitment to improving the lives of patients with cancer by providing local access to promising investigational therapies," said Dan Rhodes, Ph.D., CEO of Strata Oncology. "We are confident our network of health system partners, standardized on the Strata Trial, will help drive rapid enrollment of this important study."

David Chao, President & CEO of BioMed Valley Discoveries, commented, "We are delighted to collaborate with Strata to develop our first-in-class ERK inhibitor. Strata’s ability to rapidly identify patients with specific tumor mutations has the potential to dramatically accelerate the recruitment of patients for our trial."